Brokers Offer Predictions for BMRN FY2025 Earnings

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) – Equities research analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for BioMarin Pharmaceutical in a research report issued to clients and investors on Tuesday, January 21st. Cantor Fitzgerald analyst O. Brayer forecasts that the biotechnology company will earn $3.09 per share for the year. Cantor Fitzgerald currently has a “Overweight” rating and a $90.00 target price on the stock. The consensus estimate for BioMarin Pharmaceutical’s current full-year earnings is $2.50 per share.

BioMarin Pharmaceutical (NASDAQ:BMRN) last issued its earnings results on Tuesday, October 29th. The biotechnology company reported $0.55 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.78 by ($0.23). BioMarin Pharmaceutical had a return on equity of 8.53% and a net margin of 11.71%. The company had revenue of $746.00 million during the quarter, compared to analyst estimates of $703.37 million. During the same period last year, the business earned $0.26 earnings per share. The firm’s revenue was up 28.4% compared to the same quarter last year.

BMRN has been the subject of several other research reports. Raymond James reissued an “outperform” rating and issued a $79.00 price target on shares of BioMarin Pharmaceutical in a research note on Thursday, October 10th. Evercore ISI cut their target price on BioMarin Pharmaceutical from $115.00 to $105.00 and set an “outperform” rating for the company in a research note on Wednesday, October 30th. Canaccord Genuity Group reduced their target price on BioMarin Pharmaceutical from $93.00 to $84.00 and set a “hold” rating on the stock in a research report on Wednesday, October 30th. Royal Bank of Canada reiterated a “sector perform” rating and set a $80.00 price target on shares of BioMarin Pharmaceutical in a report on Wednesday, October 30th. Finally, UBS Group upped their target price on shares of BioMarin Pharmaceutical from $104.00 to $106.00 and gave the company a “buy” rating in a research report on Wednesday, October 30th. Seven research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $94.20.

BioMarin Pharmaceutical Price Performance

BioMarin Pharmaceutical stock opened at $62.02 on Wednesday. The company has a current ratio of 4.27, a quick ratio of 2.62 and a debt-to-equity ratio of 0.11. The company has a 50-day moving average price of $65.32 and a 200 day moving average price of $74.02. BioMarin Pharmaceutical has a 12-month low of $60.63 and a 12-month high of $94.85. The stock has a market cap of $11.82 billion, a P/E ratio of 37.14, a PEG ratio of 0.54 and a beta of 0.29.

Institutional Investors Weigh In On BioMarin Pharmaceutical

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Primecap Management Co. CA increased its stake in BioMarin Pharmaceutical by 0.4% in the third quarter. Primecap Management Co. CA now owns 18,867,435 shares of the biotechnology company’s stock valued at $1,326,192,000 after purchasing an additional 77,350 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of BioMarin Pharmaceutical by 1.9% in the 3rd quarter. Geode Capital Management LLC now owns 3,260,050 shares of the biotechnology company’s stock valued at $228,632,000 after buying an additional 60,692 shares in the last quarter. Charles Schwab Investment Management Inc. grew its position in shares of BioMarin Pharmaceutical by 4.1% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,401,628 shares of the biotechnology company’s stock valued at $98,520,000 after buying an additional 55,699 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in BioMarin Pharmaceutical by 38.9% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,034,457 shares of the biotechnology company’s stock worth $85,178,000 after acquiring an additional 289,953 shares in the last quarter. Finally, Erste Asset Management GmbH acquired a new stake in BioMarin Pharmaceutical during the 3rd quarter worth $48,527,000. Institutional investors and hedge funds own 98.71% of the company’s stock.

Insider Transactions at BioMarin Pharmaceutical

In other BioMarin Pharmaceutical news, EVP Charles Greg Guyer sold 5,278 shares of the firm’s stock in a transaction on Tuesday, November 12th. The stock was sold at an average price of $66.37, for a total value of $350,300.86. Following the sale, the executive vice president now directly owns 68,909 shares in the company, valued at $4,573,490.33. This trade represents a 7.11 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 1.85% of the company’s stock.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.